Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

S. Gabriel, E. Creagan, W. M. O'Fallon, J. Jaquith, T. W. Bunch

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

Original languageEnglish (US)
Pages (from-to)460-465
Number of pages6
JournalJournal of Rheumatology
Issue number4
StatePublished - Jan 1 1990


  • methotrexate
  • rheumatoid arthritis
  • treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Treatment of rheumatoid arthritis with higher dose intravenous methotrexate'. Together they form a unique fingerprint.

Cite this